FDA Sets Date of Advisory Committee Meeting for Donanemab in Alzheimer's Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States. Food & Drug Administration
    • Abstract:
      The article provides information on Food and Drug Administration's Advisory Committee Meeting on June 10, 2024, which will discuss the phase 3 trial of Lilly's donanemab for early symptomatic Alzheimer's disease, focusing on safety results and the unique trial design implications.